Autopsy report · NCT00296010

Liposomal Doxorubicin Compared With Observation or Cyclophosphamide and Methotrexate in Treating Older Women Who Have Undergone Surgery for Breast Cancer

“Accrual rate was too low”

The sponsor’s own words in the registry.

Life of this trial

• Registered 6 months after it had already started.
• Ran for about 6 years 4 months before it stopped.
• 77 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

ETOP IBCSG Partners Foundation

Sponsor type

University, hospital or other

Conditions

Breast Cancer

Interventions

cyclophosphamide; methotrexate; pegylated liposomal doxorubicin hydrochloride; adjuvant therapy; radiation therapy

Participants

77

Sites

33

Countries

Australia, Belgium, Hungary, Italy, New Zealand, Romania, Slovenia, Sweden, Switzerland

Trials that died the same way

• Phase 2 Study to Determine if RTB101 Reduces the Severity of COVID-19 in Older Adults Residing in Nursing Homes
  “Insufficient accrual rate” (89% match in meaning)
• A Pilot Trial of GI-4000 Plus Bevacizumab and Either FOLFOX or FOLFIRI
  “Poor accrual rate” (89% match in meaning)
• Antiretroviral Improvement Among Medicaid Enrollees
  “Insufficient rate of accrual” (88% match in meaning)
• A Study to Assess the Efficacy of Erlotinib for Leptomeningeal Carcinomatosis in EGFR Mutation Positive Non-small Cell Lung Cancer
  “low accrual rate” (88% match in meaning)
• Registry to Compare Two Surgical Treatments for GERD
  “Unexpected low accrual” (78% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.